Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
PHM142 Fall 2016 Coordinator: Dr. Jeffrey Henderson Instructor: Dr. David Hampson Narcolepsy and Orexin Autoimmunity Kunal Bhatt, Bao Thi Nguyen, Roshni Patel, Mamun Patwary November 8, 2016 Outline ● Orexin? ○ What is it? ○ Where is it? ○ What are the receptors? ● Narcolepsy and how it is related to orexin ● Orexin autoimmunity ● Treatment for Narcolepsy Orexin: What is it? ● Also known as Hypocretin (HCRT) ● Excitatory neuropeptide hormone produced in the hypothalamus ● Involved in: ○ Food consumption ■Prominent in LHA ○ Energy homeostasis ○ Arousal Orexin: Where is it? Orexin: Receptors Two orexin receptors have been identified to date (OX1R and OX2R) ● G protein with a proposed seven transmembrane ● Receptors display distinct pattern of interaction with orexins ● Orexin-A high affinity for BOTH receptors; Orexin-B 10-fold higher affinity at OX2R than OX1R ● OX1R is 100-fold selective for OX-A, OX2R has equal affinity for BOTH Orexin: Receptors ● Two subtypes of receptors account for different functions of Orexin ● OX2R deficient mice - fragmented wakefulness characteristic of narcolepsy ● OX1R knockout mice - only show mild sleep disorder ● Double knockout mice - severe deficit in sleep wake cycle Narcolepsy: Chronic Sleep Disorder High tendency to fall asleep during the daytime Nocturnal sleep fragmentation Rapid Eye Movement (REM) sleep Cataplexy Narcolepsy: Other Potential Symptoms Hypnagogic hallucinations - realistic dreams you experience as you are about to fall asleep Sleep paralysis - inability to move immediately upon awakening Narcolepsy: Causes ● Loss of orexin (hypocretin)-producing neurons in the hypothalamus ● Mutations/Deletions in the HCRT (Orexin A and B), HCRTR1 (OX1R) or HCRTR2 (OX2R) genes (not common in narcoleptics) ● Autoimmune Basis Narcolepsy: Autoimmunity Hypothesized that narcolepsy caused by autoimmune destruction of orexin neurons and receptors Has not been proven despite vast amounts of research since the 80’s Some correlations that maintain idea of autoimmune involvement Specific orexin cell loss in CSF of postmortem analysis of narcolepsy patients but other cells were still intact Ongoing research and proposed mechanisms in hopes to find a target to treat Narcolepsy: Autoimmunity Proposed Mechanism HLA genes code for MHC I and II MCH present antigens to T cells for targeting and destruction Autoimmune disease: host antigens presented to T cells Orexin tissue seen as foreign, and therefore targeted (Kornum et al., 2011) 99% of patients carry specific HLA genes associated with narcolepsy (HLA DQB1*06:02 and HLA DQA1*01:02) Narcolepsy: Treatment No treatment of cause, only treatment of symptoms Sleepiness Modinafil and amphetamine-like drug to promote wakefulness Cataplexy Tricyclic antidepressants and selective serotonin reuptake inhibitors Suppress REM sleep during the day Example: Imipramine Summary Page Orexin? Excitatory neuropeptide hormone produced in the hypothalamus Involved in: Food consumption Sleep Energy homeostasis Arousal Orexin has two forms (Orexin A and Orexin B) and two receptors (OX1R and OX2R) Orexin-A higher affinity for BOTH receptors; Orexin-B higher affinity for OX2R OX2R deficiency results in narcoleptic phenotype Summary Page Narcolepsy and how related to orexin Narcolepsy - characterized by excessive sleepiness during the daytime, fragmented sleep, REM sleep, and cataplexy Caused by damage to orexin-producing neurons in the hypothalamus, mutations in the orexin genes and of their receptors, or potentially an autoimmune response to the peptides and receptors Orexin autoimmunity Nothing proven yet despite a plethora of studies Drugs for Narcolepsy and how they work Sleepiness promotes wakefulness References Boss, C., & Roch, C. (2015, May 15). Recent trends in orexin research—2010 to 2015. Bioorganic & Medicinal Chemistry Letters, 25(15), 28752887. doi:10.1016/j.bmcl.2015.05.012 Ebrahim, I. O., Howard, R. S., Kopelman, M. D., & Sharief, K. M. (2002, May). The hypocretin/orexin system. J R Soc Med, 95(5), 227-230. Retrieved November 7, 2016. Kornum, B. R., Faraco, J., & Mignot, E. (2011, December). Narcolepsy with hypocretin/orexin deficiency, infections and autoimmunity of the brain. Current Opinion in Neurobiology, 21(6), 897-903. doi:10.1016/j.conb.2011.09.003 Lecea, L. D., & Huerta, R. (2014, February 12). Hypocretin (orexin) regulation of sleep-to-wake transitions. Frontiers in Pharmacology Front. Pharmacol., 5. doi:10.3389/fphar.2014.00016 Liblau, R. S., Vassalli, A., Seifinejad, A., & Tafti, M. (2015, March). Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy. The Lancet Neurology, 14(3), 318-328. doi:10.1016/s1474-4422(14)70218-2 Medications: Narcolepsy Network. Retrieved November 08, 2016, from http://narcolepsynetwork.org/about-narcolepsy/treatment/narcolepsymedications/ Tsujino, N., & Sakurai, T. (2009). Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system. Pharmacological reviews, 61(2), 162-176.